CLDX

Celldex Therapeutics, Inc.
CAPPED RATING

Celldex Therapeutics, Inc., a biopharmaceutical company, engages in developing therapeutic monoclonal and bispecific antibodies for the treatment of various diseases. Its drug candidates include antibody-based therapeutics to treat patients with inflammatory diseases and various forms of cancer. The company's clinical development programs CDX-0159, a Phase I monoclonal antibody that binds the receptor tyrosine kinase KIT and inhibits its activity; CDX-1140, a human agonist monoclonal antibody targeted to CD40, a key activator of immune response, which is found on dendritic cells, macrophages, and B cells, as well as is expressed on various cancer cells; and CDX-527, a bispecific antibody, which uses the company's proprietary active anti-PD-L1 and CD27 human antibodies to couple CD27 costimulation with blockade of the PD-L1/PD-1 pathway to help prime and activate anti-tumor T cell responses through CD27 costimulation. The company has research collaboration and license agreements with University of Southampton to develop human antibodies towards CD27; Amgen Inc. with exclusive rights to CDX-301 and CD40 ligand; and Yale University. Celldex Therapeutics, Inc. was incorporated in 1983 and is headquartered in Hampton, New Jersey.

Celldex Therapeutics, Inc. (CLDX) is rated C- (2.0/5) on Deltasharpe Prism, scored against Healthcare sector peers. Its strongest pillar is Growth (B); its weakest is Value (F).

Quantitative Factor Evaluation • Updated

Overall Rating
2.0 / 5.0
C-
Value
F
Factor Score 0.0 / 5.0
Growth
B
Factor Score 3.3 / 5.0
Profitability
D+
Factor Score 1.6 / 5.0
Momentum
C
Factor Score 2.3 / 5.0
Revisions
C+
Factor Score 2.6 / 5.0

Prism grades are automated quantitative screens, not buy, sell or hold recommendations, and not investment advice. Data may be delayed or contain errors. Terms

Ratings of B- and above are for members.

Register free to see every rating — your first 2 weeks of Premium are on us.

Register — 2 weeks free

Underlying Financial Metrics

P/E Ratio -7.3
EV / EBITDA -5.3
Rev Growth YoY N/A
Gross Margin 0.0%
Price Return 3M -31.7%
Price Return 12M 33.8%
Catalyst Signal 0.00
Market Cap $2.4B
TTM Revenue $158.0K
Price / Sales 15.2K
ROE -49.5%

Historical Factor Score Progression

Date Value Growth Profitability Momentum Revisions Overall
2026-11-11 F (0.0) B (3.3) D+ (1.6) C (2.3) C+ (2.6) C- (2.0)
2026-11-04 F (0.0) C (2.3) D+ (1.7) C (2.4) C+ (2.7) D+ (1.8)
2026-10-28 F (0.0) C (2.3) D+ (1.7) C (2.4) C+ (2.7) D+ (1.8)
2026-10-21 F (0.0) C (2.2) D+ (1.7) C+ (2.8) C+ (2.6) C- (1.9)
2026-10-14 F (0.0) C (2.3) D+ (1.7) C+ (2.7) C+ (2.6) C- (1.9)
Page 1 of 8
…